http://www.eosneuroscience.com/technology/
Eos believes that a better answer is an optogenetic approach. Our therapy enables the expression of a light activated protein in retinal bipolar cells, a specific subpopulation of neurons in the retina that receives input from photoreceptors. This therapy allows the eye to again be activated by light, even though the natural photoreceptors are gone. This therapy has achieved proof of concept in mice and is in preclinical development to treat blindness caused by human retinitis pigmentosa and macular degeneration.
该技术已经完成了小鼠概念证明，即将进入临床试验阶段 |
